Madrigal Pharmaceuticals Reaches Analyst Target Price
January 22, 2018 at 09:22 AM EST
In recent trading, shares of Madrigal Pharmaceuticals Inc (MDGL) have crossed above the average analyst 12-month target price of $113.33, changing hands for $124.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..